

Gonorrhoea - Pipeline Insight, 2021

<https://marketpublishers.com/r/G9DBC4297FC5EN.html>

Date: June 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: G9DBC4297FC5EN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Gonorrhoea - Pipeline Insight, 2021," report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Gonorrhoea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Gonorrhoea Understanding

Gonorrhoea: Overview

Gonorrhoea is a sexually transmitted infection (STI), usually passed on through unprotected vaginal, anal or oral sex. It is caused by bacteria called *Neisseria gonorrhoeae* or gonococcus. Gonorrhoea used to be known as 'the clap'. Typical symptoms of gonorrhoea include a thick green or yellow discharge from the vagina or penis, pain when peeing and, in women, bleeding between periods. Testing for gonorrhea is done by swabbing the infected site (rectum, throat, and cervix) and identifying the bacteria in the laboratory. Gonorrhoea is usually treated with a single antibiotic injection or a single antibiotic tablet.

'Gonorrhoea - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive

insights of present scenario and growth prospects across the indication. A detailed picture of the Gonorrhoea pipeline landscape is provided which includes the disease overview and Gonorrhoea treatment guidelines. The assessment part of the report embraces, in depth Gonorrhoea commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gonorrhoea collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Gonorrhoea R&D. The therapies under development are focused on novel approaches to treat/improve Gonorrhoea.

Gonorrhoea Emerging Drugs Chapters

This segment of the Gonorrhoea report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Gonorrhoea Emerging Drugs

Gepotidacin: GlaxoSmithKline

Gepotidacin (GSK2140944) belongs to class of antibiotics, called triazaacenaphthylene topoisomerase inhibitors. Gepotidacin works by selectively interacting with two key bacterial enzymes, DNA gyrase and topoisomerase IV (type II topoisomerases), responsible for bacterial replication. The novel MOA confers activity against most target pathogens resistant to established antibiotics, including fluoroquinolones. The drug is in Phase III clinical studies for the treatment of uncomplicated urinary tract infection (uUTI)/gonorrhoea.

Zoliflodacin: Entasis Therapeutics

Zoliflodacin (ETX0914) is an orally bioavailable antibacterial agent. It is a novel spiropyrimidinetrione bacterial DNA gyrase/topoisomerase inhibitor. The drug is in Phase III clinical developmental studies for the treatment of gonorrhoea.

Further product details are provided in the report..

Gonorrhoea: Therapeutic Assessment

This segment of the report provides insights about the different Gonorrhoea drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Gonorrhoea

There are approx. 12+ key companies which are developing the therapies for Gonorrhoea. The companies which have their Gonorrhoea drug candidates in the most advanced stage, i.e. Phase III include, GlaxoSmithKline.

Phases

DelveInsight's report covers around 12+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Gonorrhoea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs

such as

Oral

Parenteral

Intravitreal

Subretinal

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Gonorrhoea: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Gonorrhoea therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gonorrhoea drugs.

Gonorrhoea Report Insights

- Gonorrhoea Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Gonorrhoea Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

- How many companies are developing Gonorrhoea drugs?

- How many Gonorrhoea drugs are developed by each company?

- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gonorrhoea?

What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Gonorrhoea therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Gonorrhoea and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Evofem Biosciences

GlaxoSmithKline

Entasis Therapeutics

Alopexx Pharmaceuticals

Nobelex Biotech

Summit Therapeutics

TherapyX

AchilleS Vaccines

Recce Pharmaceuticals

VenatoRx Pharmaceuticals

Key Products

EVO 100

Gepotidacin

Zoliflodacin

F 598

Research programme: Enoyl-ACP reductase inhibitors

SMT 571

GneX 12

Gonorrhoea vaccine

RECCE 435

PBP-539

Contents

Introduction

Executive Summary

Gonorrhoea: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Gonorrhoea – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Gonorrhoea companies' collaborations, Licensing, Acquisition -Deal Value Trends

Gonorrhoea Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Gepotidacin: GlaxoSmithKline

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Mid Stage Products (Phase II)

Comparative Analysis

F 598: Alopexx Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Early Stage Products (Phase I)

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Preclinical/Discovery Stage Products

Comparative Analysis

GneX 12: TherapyX

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Inactive Products

Comparative Analysis

Gonorrhoea Key Companies

Gonorrhoea Key Products

Gonorrhoea- Unmet Needs

Gonorrhoea- Market Drivers and Barriers

Gonorrhoea- Future Perspectives and Conclusion

Gonorrhoea Analyst Views

Gonorrhoea Key Companies

Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Gonorrhoea
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Gonorrhoea
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Gonorrhoea - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/G9DBC4297FC5EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G9DBC4297FC5EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970